Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 1999

View Archived Issues

Strong growth continues for Roche during Q3 1999

Immunex continues Enbrel research during Q3; sBLA filed for additional indication

GelTex files for FDA approval of two products during Q3 1999

AEterna steps up AE-941/Neovastat development

Cell Pathways files first NDA during Q3 1999

Preclinical data for FTY-720 presented at recent Japanese meetings

Wyeth is first to cross the finish line with meningococcal group C conjugate vaccine

Biogen places anti-CD40 ligand MAb studies on hold

Orally active inhibitors of rhinoviral replication discovered at Lilly

AstraZeneca files first application for improved PPI

Development of potential new antiaddictive agent supported by NIDA

Development status update for antiglaucoma drug candidate

Q3 1999 at Amgen sees new product in phase III

Breast cancer patients now being sought for Korean trials of Genexol

Inhale acquires novel particle formulation technology for lung delivery

Approval recommended for Bayer's Avelox

SB reports temporary setback in European launch of Avandia

Approvable letter voices FDA concerns about safety of Ergoset; Ergo Science to study options

Anti-HIV pseudopeptide has a unique mechanism of action

Another major milestone announced for Wyeth Lederle Vaccines' pneumococcal vaccine

Korean investigators identify potent anti-HSV agent from natural source

Canadian approval sought for new anti-HBV product

Mechanistically novel iNOS inhibitors identified during Pharmacopeia/Berlex joint project

Phase I pharmacokinetic, pharmacodynamic and toxicological data published for ISIS-5132

FDA okays new antipsoriatic for clinical testing

Bradykinin antagonist NPC-18884 effective in various rodent models of nociception, edema

Orally active DPP-IV inhibitor presented at EASD meeting heads for clinic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...